PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
81.18%
ROE above 25% – Outstanding profitability. Warren Buffett would verify if this return is sustainable. Check competitive moat and profit margins.
22.76%
ROA above 20% – Exceptional asset efficiency. Peter Lynch would check if this is sustained by a durable growth strategy.
-102.19%
Negative ROCE suggests negative EBIT or an inflated capital base. Benjamin Graham would check if the firm is structurally unprofitable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.